Aurobindo Pharma gets USFDA nod for anti-coagulant injection

Our Bureau Hyderabad | Updated on July 30, 2018 Published on July 30, 2018

Aurobindo Pharma Ltd has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Bivalirudin injection. The approved ANDA is a generic equivalent to the reference listed drug (RLD) product Angiomax Injection of The Medicines Company.

Bivalirudin injection is indicated for use as an anti-coagulant in some patients. The estimated market size of the Bivalirudin injection is $101 million for the 12 months ending May 2018, according to IQVIA. The product will be launched in September 2018.

Aurobindo now has a total of 381 ANDA approvals (348 final approvals, including 17 from Aurolife Pharma LLC and 33 tentative approvals) from USFDA.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on July 30, 2018
This article is closed for comments.
Please Email the Editor